ABSTRACT. Granulocyte colony-stimulating factor (G-CSF) is widely used to mobilize peripheral blood stem cells, and expected to restore cardiac function for patients with coronary artery diseases as a consequence of progression of atherosclerosis. Safety issues related to the administration of G-CSF to these patients, however, are still under study. The animal model for atherosclerosis was produced by feeding miniature swine a high-cholesterol diet for 3 months. G-CSF (5 or 10 µg/kg/day) was given to the animal model by daily subcutaneous injections for 10 days and 20 main arteries were evaluated pathologically. In addition, the general toxicological effects were studied on clinical signs, body weight, hematology, blood chemistry and pathology. In the G-CSF-treated groups, a variety of changes related to the major pharmacological activity of G-CSF including an increase in white blood cell (WBC) counts were observed. In many arteries, atherosclerotic lesions similar to Type I-V of the proposed classification by the American Heart Association were observed. No effects of the G-CSF treatment were seen on the histopathological findings, incidence, severity or distribution of atherosclerotic lesions. In addition, no infiltration of neutrophils to the lesions was observed. These findings suggest that the administration of G-CSF causes neither exacerbation or modification of atherosclerotic lesions nor adverse changes despite that a sufficient increase in WBC counts could be achieved in the peripheral blood. KEY WORDS: atherosclerosis, atherosclerotic lesions, G-CSF, high cholesterol diet, miniature swine.
Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor that can act selectively on cells of the neutrophil lineage [1] and also facilitate to mobilize multipotent stem cells of bone marrow into peripheral blood [9, 11] . Stem cells, which may differentiate into myocardial cells or endothelial cells [4, 9, 12, 23] , have been the target of intensive investigation for the preclinical and clinical use in regenerative medicine [3, 12, 19] . Mobilization of stem cells by G-CSF has been considered to become a potent therapy for patients with acutely or chronically damaged myocardium due to its easy and universal application.
However, it has been reported recently that in the clinical trial for coronary artery disease (CAD) patients performed by the National Institutes of Health (NIH) there occurred a serious adverse event which might be associated with G-CSF administration: 1 out of 16 patients experienced non-ST-segment elevation myocardial infarction (MI) and another patient died of MI [6] . This fact has caused anxiety concerning the safety of G-CSF among people engaging in regenerative medicine. The clinical concern about patients with CAD is that they have, more or less, attenuation of the coronary arteries as a consequence of progression of atherosclerosis [14] . There should be a variety of risk factors which have to be validated before safe and universal application of G-CSF to patients with cardiovascular system disorders. The present study was carried out to evaluate the effects of G-CSF on atherosclerotic lesions, using a miniature swine atherosclerosis model which has been reported to exhibit similarities to human in the distributions and properties of atherosclerotic lesions [22] . In addition, the general toxicological effects of G-CSF on this model were also evaluated.
MATERIALS AND METHODS
Animals: Nine 3-month-old Göttingen miniature swine (5 males and 4 females) were obtained from Chugai Research Institute for Medical Science, Inc. (Nagano, Japan). They were housed in cages (1 animal/cage) in an animal room maintained in a controlled environment of 22 ± 3°C, humidity of 35 to 70%, 10 to 15 air changes per hour, and a 12 hr light cycle (7:00 to 19:00). All swine were fed a 420 g cholesterol diet (High-cholesterol diet for miniature swine, Nisseiken Co., Ltd., Tokyo, Japan) once per day and water ad libitum. The high-cholesterol diet was continuously fed to them during the period of G-CSF administration.
G-CSF: Recombinant human G-CSF manufactured by Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan) was used for this study. This agent was dissolved in phosphate buffer to final concentrations of 50 and 100 µg/ml. were produced by feeding a high cholesterol diet for 3 months. Groups of 3 swine each received daily subcutaneous injections of G-CSF in the cervix at a dose of 5 or 10 µg/ kg/day for 10 days. Although the major concern of side effect of G-CSF application to the patients is an excessive elevation of WBC counts, the doses and treatment period of G-CSF in the present study were determined taking into consideration the upper limit of WBC counts acceptable to medical doctors of the regenerative medicine (approximately 300 × 10 2 /µl) and the estimated clinical treatment period (4-6 days) [20] . The results of preliminary study confirmed the adequacy of the doses and treatment period selected for the present study. The injection volume was adjusted to 0.1 ml/kg. In addition to the G-CSF-treated groups, a vehicle control group was prepared. During the administration period, clinical signs of all animals were observed daily before and after the dosing. All animals were weighed at 10, 4 and 1 days before commencement of administration (day -10, day -4, and day -1) and at 3, 7, and 10 days of administration (day 3, day 7 and day 10). Blood samples were collected from each animal through the anterior sinus of the vena cava on days -10, -4 (measured as pretreatment values), 3, 7, and 10, and were subjected to hematology and/or blood chemistry. Electrocardiography was performed on days -4 and 10. All animals were necropsied the day after the final administration.
The present procedures of animal experiment were approved by the Ethical Committee for Treatment of Laboratory Animals at Chugai Pharmaceutical Co., Ltd.
Hematology: Blood samples for hematological analysis were collected in tubes treated with EDTA-2K or sodium citrate on days -10, -4, 3, 7, and 10. Citrated plasma was collected following centrifugation of samples at 4°C for 10 min at 1,900 × g. The following 19 hematological parameters were determined: Red blood cell count, white blood cell (WBC) count, platelet count, hemoglobin concentration, hematocrit, mean corpuscular volume, mean cell hemoglobin, mean cell hemoglobin concentration, differential leukocyte ratio for stab cells (Stab), segmented cells (Seg), eosinophils (Eosin), basophils (Baso), monocytes (Mono), lymphocytes (Lymph), erythroblast count (Ebl), active partial thromboplastin time (APTT), prothrombin time (PT), and fibrinogen level (FIB). WBC counts were determined using a Bayer H1E Hematology analyzer (Bayer Diagnostics, Tarrytown, NY). APTT, PT and FIB were determined by means of an Amelung-Coagulometer KC 10 (Amelung GmbH, Lemgo, Germany). Stab, Seg, Eosin, Baso, Mono, Lymph, and Ebl were counted under light microscopy and the ratio of each differential leukocyte or erythroblast count to the total leukocyte count was calculated. All other parameters were analyzed using a Sysmex K-4500 automated hematology analyzer (Sysmex Co., Long Grove, Illinois, U.S.A.).
Blood chemistry: Blood samples for biochemical analysis were collected on days -10, -4, and 10. Samples were allowed to clot at room temperature for 60 min. Serum was separated from the samples by centrifugation at 4°C for 10 min at 1,900 × g and then frozen at -70°C prior to analysis. Serum levels of the following 23 biochemical parameters were determined: aspartate-aminotransferase (AST), alanine-aminotransferase (ALT), alkaline phosphatase (Al-P), gamma-glutamyl transpeptidase (GGT), lactic dehydrogenase (LDH), creatinine-phosphotransferase (CPK), glucose (Glu), total bilirubin (T-Bil), total cholesterol (T-Cho), triglycerides (TG), low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), blood urea nitrogen (BUN), creatinine (CRN), inorganic phosphorus (IP), calcium (Ca), sodium (Na), potassium (K), chloride (Cl), total protein (TP), albumin (Alb), and albumin:globulin ratio (A/G). Analyses of all other parameters were performed using an automatic analyzer (Hitachi 7170, Tokyo, Japan).
Electrocardiography: On days -4 and 10, all animals were initially preanesthetized by an intramuscular injection of 10 mg/kg ketamine hydrochloride and 0.05 mg/kg atropine sulfate and then anesthetized with isoflurane in a respired gas mixture. Electrocardiogram by standard limb lead was monitored under stable isoflurane anesthesia with a BIOVIEW1000 composite monitor (NEC Corporation, Tokyo, Japan).
Pathology: On the day following the final administration, all animals were preanesthetized by an intramuscular injection of 10 mg/kg ketamine hydrochloride and 0.05 mg/kg atropine sulfate and then sacrificed by exsanguination through the left axillary artery or vein. At necropsy, 20 arteries (common carotid, branchiocephalic trunk, subclavian, axillary, aortic arch, thoracic aorta, pulmonary, internal carotid, brachial, abdominal aorta, celiac, anterior cerebral, basilar, renal, cranial mesenteric, external iliac, internal iliac, femoral, right coronary, paraconal interventricular branch), hearts, livers, spleens, kidneys, lungs, brains, and bone marrow (femur) were removed from all animals. The hearts, livers, spleens, kidneys, and lungs were weighed and the relative organ weights/100g BW were calculated. All organs removed were fixed in 20% neutral buffered formalin (20% NBF), embedded in paraffin, sectioned, and stained with hematoxylin and eosin (HE). As to the brains, the cerebral cortex and medulla oblongata, which lie directly on the anterior cerebral artery and basilar artery respectively, were observed grossly and processed as described above. Some of the arterial sections were stained with elastica van Gieson (EVG) to assess in detail changes in the elastic layers and extracellular matrix (ECM), or were subjected to immunohistochemical analysis as mentioned below. After fixation in 20% NBF, additional samples of several arteries were immersed in 10% sucrose in phosphate-buffered saline (PBS; 0.01 M, pH 7.4) for 4 hr at 4°C, followed by 15% sucrose in PBS for 4 hr at 4°C and 20% sucrose in PBS overnight at 4°C, embedded in Tissue-Tek OCT compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan), sectioned on a microtome in a cryostat, and stained with Oil red O to identify fat deposits in the arterial intima.
Immunohistochemical staining was performed according to the labeled streptavidin-biotin (LSAB) method with a Dako LSAB-2 kit (Dako, Carpinteria, CA, U.S.A.). Antibody against α-smooth muscle actin (α-SMA) (clone 1A4, Dako Cytomation Co., Ltd., Kyoto, Japan) was applied as the primary antibody. The immunoreaction was visualized by peroxidase-diaminobenzidine reaction. The sections were finally counterstained with hematoxylin.
The severity of the atherosclerotic lesions was graded into 3 classes (Table 1) as follows: Grade 1; intimal thickening and destruction of elastic layers with infiltration of foamy cells into the intima (Fig. 1a and 1b) , Grade 2 (intermediate); all components of Grade 1 lesions with an increase in intimal spindle-shaped cells accompanied by an increase in ECM and occasional calcification (Fig. 1d) , Grade 3; a prominent build-up of fibrous cap with substantial increases in ECM elaborated by dense distribution of collagen and elastic fibers and remarkable calcification (Fig.  1f, 1h and 1i) .
RESULTS

Clinical signs and body weights:
No abnormal clinical signs were observed in any group throughout the study period. All animals of both control and treated groups showed normal body weight gain.
Hematological findings: In G-CSF-treated groups, an increase in WBC (mainly segmented neutrophils) counts was observed (Fig. 2) . WBC counts gradually increased during the time course of G-CSF administration, reaching approximately 300 × 10 2 /µl (range, 233-388 × 10 2 /µl) on day 3, 400 to 700 × 10 2 /µl on day 7 and 400 to 900 × 10 2 /µl on day 10. No definite dose response was observed between the dose levels of 5 and 10 µg/kg. In addition, no clear differences in WBC count elevation profiles were observed between either sex. No other changes of the treatment were noted in hematology.
Blood chemistry findings: None of the parameters examined showed any distinct difference between the control and G-CSF-treated groups.
However, the levels of T-Cho, HDL, LDL, and GGT in all swine of the present study were higher than those of the baseline data of the swine fed on ordinary diets [21, 24] ( Table 2 shows data extracted from the results of bloodchemical analysis on day -4).
Electrocardiography:
No abnormal electrocardiographic patterns were observed in any animal on both days -4 and 10.
Pathological findings of atherosclerotic lesions: In many arteries, areas of yellow-white discoloration were grossly observed on the inner surface, some of which were seen as raised plaques (especially remarkable in abdominal arteries). There were no differences in gross findings between the control and G-CSF-treated groups.
Histopathologically, intimal thickening, infiltration of foamy cells into the intima, increase of ECM, increase of spindle-shaped cells, calcification, cholesterol clefts, and build-up of fibrous cap were observed. Foamy cells accumulating in the intima were positive for Oil red O staining (Fig. 1c) , indicating that they were lipid-laden cells. Moreover, in the lesions of Grade 2 and 3, extracellular space also contained Oil red O positive droplets that frequently formed into small dispersed pools or larger and confluent cores (lipid cores) (Fig. 1g) . The immunohistochemical staining revealed spindle-shaped cells that were positive for α-SMA, indicating that they derived from smooth muscle cells (Fig.  1e) . In the comparison of the control group with the G-CSFtreated groups, no changes in histopathological findings and no increase in incidence of each finding following G-CSF administration were observed (Table 3 ). In addition, no infiltration of neutrophils to the lesions was seen in any of the groups.
No clear differences in gross and histopathological findings of arteries were observed between either sex within the same group.
Incidence and severity of atherosclerotic lesions: Incidence and severity of atherosclerotic lesions are shown in Table 4 . Grade 1-3 lesions were observed in the control group with incidence highest in Grade 1, average in Grade 2, and lowest in Grade 3. These results were similar to those of the G-CSF-treated groups. No differences in incidence and severity of the lesions were seen in the two G-CSFtreated groups.
Distribution of atherosclerotic lesions: Atherosclerotic lesions were frequently distributed in the abdominal aorta, aortic arch, celiac artery, right coronary artery, and paraconal interventricular branch. No definite differences were observed in distribution of the lesions between the control and G-CSF-treated groups (Table 5) .
Pathological findings and organ weights of spleens, livers, hearts, lungs, brains and kidneys:
In the G-CSF-treated groups, the enlargement and increased weights of spleen, increase in the number of granulocytic cells in bone marrow, and increased extramedullary hematopoiesis in liver and spleen were observed (data not shown).
In all groups including the control group, whitish yellow livers and pale red spleens were grossly observed. Microscopically, fatty change in hepatocytes, aggregations of foamy kupffer cells in liver sinusoid, and aggregations of foamy cells in red pulps were observed.
No abnormal pathological changes were observed in the hearts, lungs, brains, and kidneys of any animals. intimal thickening P P P infiltration of foamy cells P P P destruction of elastic layers P P P increase of spindle cells P P increase of extracellular matrix P P calcification P P formation of fibrous cap P Abbreviation: P, present. EVG. Bar=50 µm.
DISCUSSION
In this study, we evaluate the effects of G-CSF on atherosclerotic lesions as well as on the general toxicology in an animal model for atherosclerosis produced by feeding miniature swine a high-cholesterol diet for 3 months.
In all animals, increased levels of lipid parameters such as T-Cho, HDL and LDL, and lipid deposition in organs and tissues as demonstrated by areas of yellow-white discoloration and raised plaques on the inner surface of many arteries, whitish-yellow livers, pale red spleens, fatty change of hepatocytes, aggregations of foamy Kupffer cells in liver sinusoid, and aggregations of foamy cells in red pulps were observed. These changes are considered a consequence of feeding a high-cholesterol diet for a given period of time [22] and ensured that all animals had features sufficient to be a model for atherosclerosis. In addition, increased levels of GGT were found in all animals, which were deemed secondary effects due to lipid deposition in organs or progression of atherosclerotic lesions [22] .
In the G-CSF-treated groups, a significant increase in WBC counts was observed, reaching approximately 300 × 10 2 /µl on day 3, 400-700 × 10 2 /µl on day 7, and 400-900 × 10 2 /µl on day 10. These values were nearly equal to or far greater than the acceptable range of WBC counts (within approximately 300 × 10 2 /µl) for medical doctors of the regenerative medicine. In addition to an increase in WBC counts, the enlargement and increased weights of spleens, increased number of granulocytic cells in bone marrow, and increased extramedullary hematopoiesis in liver and spleen, that are also related to the major pharmacological activity of G-CSF were observed in the G-CSF-treated groups. However, no adverse changes were observed in any of the tests carried out in this study.
The atherosclerotic lesions seen in this model were similar to Types I-V of the proposed classification by the American Heart Association (AHA) [16] [17] [18] (Table 6 ). Grade 1 lesions consisting primarily of foamy cells were similar to Type I or II of the AHA classification grossly designated as fatty streaks. Grade 2 lesions, containing increased spindleshaped cells (derived from smooth muscle cells) and accumulations of extracellular lipid droplets as well as infiltration of foamy cells, were close to Type III (preatheroma) or IV (atheroma). However, at this grade, the accumulation of extracellular lipid was not as remarkable as in human Type IV lesions, characterized by a large, confluent, and disruptive core of extracellular lipids including cholesterol crystals. In contrast, in this study Grade 2 lesions seemed to have a more remarkable increase in smooth muscle cells and ECM than Type III or IV. This increase is possibly promoted at an earlier stage during the course of the disease in miniature swine compared with human atherosclerotic lesions. In fact, it is known that the increase in smooth muscle cells or collagenous fibers is modest in Type III or IV 2 /µl represents the estimated upper limit among medical doctors using G-CSF as a regenerative medicine. Table 2 . Comparison of T-Cho, HDL, LDL and GGT levels between high cholesterol-fed and normal miniature swine
449 ± 95.2 (9) 106 ± 7 (9) 189 ± 67 (9) 85.8 ± 19.7 (9) normal b) 81.5 ± 7.1 c) (6) 29 ± 9 d) (14) 17 ± 8 d) (14) 37.8 ± 6.0 c) (6) Each value represents the mean ± SD. Parentheses indicates the number of miniature swine examined. a) The values for high cholesterol-fed miniature swine were extracted from the results of blood-chemical analysis on day -4. b) Extracted data from references/baseline data collected at Chugai Reserch Institute for Medical Science, Inc (CMS): c), the data from an experiment manual for miniature swine 21 ; d), the data from Cardiovascular Research 2002; 56(1): 135-144 24 .
lesions [17] . Grade 3 lesions, characterized by build-up of fibrous cap and distinct lipid core, were similar to Type V lesions, referred to as fibroatheroma. Grade 3 was the most advanced stage found in this study. However, there were no disruption of the lesions, hematoma or hemorrhage, or thrombotic deposits (lesions corresponding to Type VI) in any of the arteries examined. In this study, no clear sex differences were observed in reactivity against G-CSF administration (such as WBC count elevation profiles) as well as in gross and histopathological findings of arteries. Accordingly, it can be reasonable to put the results of both sexes together and evaluate their findings as a relevant group.
As to the effect of G-CSF on atherosclerotic lesions, no differences were seen in histopathological findings, incidence, severity, or distribution between the control and the G-CSF-treated groups. Moreover, G-CSF treatment did not become a trigger of neutrophil infiltration to the lesions. These results strongly suggest that the administration of G-CSF does not lead to exacerbation or modification of atherosclerotic lesions despite that a sufficient increase in WBC counts could be achieved in the peripheral blood.
On the other hand, in the clinical trials performed on patients with CAD, 2 out of the 16 patients injected with G-CSF experienced serious cardiac events [6] . Another study reported that the rate of in-stent restenosis in the G-CSFtreated group was unexpectedly increased, raising the specter of harmful effects in clinical scenarios in which vessel injury exists [8] . Moreover, the preclinical study in apolipoprotein E-deficient mice, which were maintained on a highfat diet, demonstrated an exacerbation of the atherosclerotic lesions after treated with G-CSF and GM-CSF [5] . In contrast, there have been some reports in support of our data which indicate no adverse effects of G-CSF on atherosclerotic lesions. In the study with 23 acute MI patients in a nonrandomized trial, no severe side effects of G-CSF were observed [10] . In fact, it was revealed that treatment with G-CSF significantly improved regional wall motion, myocardial perfusion, and ejection fraction at 3 months followup. Two additional randomized placebo-controlled studies in which G-CSF was administered to the patients after MI and successful percutaneous intervention demonstrated neither benefit nor adverse effects [7, 13, 25] . In the previous animal studies, Shindo et al. reported that a long-term administration of GM-CSF for 7 months in a rabbit model of atherosclerosis had no adverse effect but rather a protective effect [15] . Similarly, a recent publication demonstrated that knocking out the GM-CSF gene in mice exacerbated atherosclerosis [2] . Thus, results from clinical and preclinical studies are conflicting in terms of both potential benefit and adverse outcomes. In our study, although no adverse effects of G-CSF administration on atherosclerotic lesions were observed, the terminal stange of atherosclerosis (Type VI) could not be obtained in the animals. Therefore, it is unclear whether or not G-CSF administration or the increase in WBC counts may affect the feature of Type VI lesions.
To determine the clinical effects of G-CSF administration and the increase in WBC counts on atherosclerotic lesions, further study and the accumulation of clinical data are indispensable.
Collectively, the present study demonstrates that the administration of G-CSF or an increase in WBC counts does not exacerbate or modify atherosclerotic lesions and nothing other than the efficacy of G-CSF was observed in the G-CSF-treated groups. However, since serious adverse events that might be associated with G-CSF administration have been reported in the CAD patients, the administration of G-CSF to patients with serious cardiovascular system disorders should be avoided or carried out under the careful monitoring of cardiovascular and inflammatory parameters. 
